pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
Hepatology · news · pharmadog
← back to Hepatology
News · Hepatology
122
stories
17h
Ultragenyx, after setbacks, nabs first gene therapy approval
biopharma dive
19h
STAT+: Pharmalittle: We’re reading about a Regeneron rare disease drug, an Ultragenyx gene therapy, and more
stat
20h
Ultragenyx bags first gene therapy approval as previously rejected Sanfilippo asset awaits decision
biospace
1d
FDA Approves First Therapy for Patients aged 8 years and older with Glycogen Storage Disease Type Ia
fda press
1d
Optimal Balance Pharmacy Issues Voluntary Nationwide Recall of Certain Lots of Compounded Glutathione 200 mg/mL Multi-Dose Vials Due to Elevated Endotoxin Levels
fda recalls
1d
Kolon TissueGene cuts 37 US staffers after Phase 3 fail
biospace
2d
Leo Pharma buys rare skin disease drug in $435M deal
biopharma dive
2d
LEO adds to dermatology portfolio with $435M deal for late-stage rare disease drug
biospace
3d
Assessing shared failures with AI is key to cell and gene therapy’s evolution
biospace
4d
Lilly pens $370M deal with OmniAb for ion channel collab, but details remain vague
fiercebiotech
6d
Skye and Redx form new entity with $125M to advance fibrosis assets
fiercebiotech
6d
After 2 undisclosed gene therapy deaths, can China’s alternative regulatory path still be trusted?
fiercebiotech
8d
Opinion: How to disrupt the health misinformation business model
stat
9d
With tech backing, AI biotechs force biopharma into ‘fail-fast’ drug development
biospace
9d
AbCellera’s menopause medicine ‘sets new efficacy bar’ for hot flashes
biospace
10d
Sionna’s cystic fibrosis failure is a windfall for Vertex’s blockbuster franchise
biospace
11d
STAT+: The promise of radiopharmaceuticals smacks into safety concerns
stat
11d
AbCellera women’s health data top ‘most aggressive upside scenario,’ putting Astellas and Bayer on notice
fiercebiotech
11d
Silence brings the noise to Takeda with phase 2 blood cancer win
fiercebiotech
13d
‘Significant’ demand for Revolution drug; Intellia pinpoints liver toxicity culprit
biopharma dive
13d
Intellia finds genetic suspect for liver safety signals with ATTR gene therapy
biospace
14d
Intellia identifies genetic risk factor for liver complications in CRISPR trial
endpoints
14d
Opinion: One year since Kennedy canceled mRNA vaccine projects, science shows how wrong he was
stat
15d
Attovia adds to biotech IPO momentum with $289M offering
biopharma dive
15d
Bespoke gene-editing outfit abandons lead program, cuts ‘several’ employees
biospace
16d
5 NextGen winners who went public this year (and which ones are hiring)
biospace
18d
5 companies advancing ATTR assets in the wake of Wainua’s fail
biospace
20d
Moderna maintains 10% growth target despite Phase 3 norovirus miss
biospace
20d
‘It’s making a difference’: Madrigal CEO talks strategy behind MASH shopping spree
fiercebiotech
21d
Opinion: Limb girdle muscular dystrophy patients face a maddening reality
stat
← prev
page 1 of 5
next →
